Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
A case report suggests that endoscopic techniques may have utility in the diagnosis of the gastric involvement that can occur in follicular lymphoma.
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.
In site-specific analyses, significant correlation seen for poor oral health with hepatocellular carcinoma.
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Acelarin (NUC-1031; NuCana) has been granted Orphan Drug designation by the FDA for the treatment of biliary tract cancer.
During 2013, only 4.9% of older patients with the specified solid tumor cancers received chemotherapy within the last 14 days of life.
The incidence of early onset colorectal cancer per 100,000 people increased from 6.7 during 1995-1996 to 11.5 during 2014-2015 for residents of the state of WA.
Researchers sought to measure adherence to topical management regimens among patients with HFSR due to treatment with regorafenib.
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
The VISNU-1 trial is “the first study performed in a population selected by baseline [circulating tumor cell] count,” according to lead study author Javier Sastre, MD, PhD.
The underuse of the procedure in this patient population was independent of tumor biology and socioeconomic factors.
Use of statins before or after colorectal cancer (CRC) diagnosis is linked to a lower risk for premature death, from either cancer or other causes.
Elderly and frail patients with advanced gastroesophageal cancer who received lower doses of chemotherapy did not have worse survival outcomes.
Colorectal cancer incidence is increasing among young adults in certain high-income countries.
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
None of the 45 patients who had a negative postoperative ctDNA value experienced a relapse after a median follow-up of 49 months.
The addition of nab-paclitaxel to gemcitabine-cisplatin appeared to confer clinical benefit in patients with advanced biliary tract cancers.